8QQ Stock Chart & Stats
€5.06
€0.02(0.40%)
At close: 4:00 PM EDT
€5.06
€0.02(0.40%)
Day’s Range― - ―
52-Week Range€2.49 - €7.65
Previous CloseN/A
Volume130.00
Average Volume (3M)822.00
Market Cap
€1.43B
Enterprise Value€668.18
Total Cash (Recent Filing)€504.73M
Total Debt (Recent Filing)€140.18M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume663
30 Day Avg. Volume822
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.94Price Target Upside76.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.5
Revenue Forecast (FY)€28.12M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Committed FundingA roughly $655M available liquidity position provides multi-year runway to advance internal programs and absorb trial timing variability. This reduces near-term dilution pressure, supports steady R&D investment, and allows the company to execute clinical milestones without immediate financing needs.
ABCL635 Phase I Strength And Clear Phase II CatalystRobust Phase I tolerability, PK/PD and progression to a randomized Phase II create a durable scientific milestone. A positive Phase II would materially de-risk the program, unlock development options or partnerships, and validate platform credibility for similar endocrine/neurologic targets.
Strategic Jazz Collaboration Validates Platform And Funds DiscoveryA sizable non-dilutive collaboration with Jazz both provides near-term cash and validates AbCellera's T-cell engager discovery capabilities. Long-term, such partnerships diversify revenue streams, create milestone/royalty upside, and strengthen commercial pathway for multispecific oncology assets.
Bears Say
Persistent Negative Cash GenerationSustained negative operating and free cash flow means the business does not self-fund development and relies on the balance sheet or external funding. If clinical timelines slip or milestones are delayed, continued burn increases financing risk and can pressure strategic flexibility.
Large Recurring Operating And Net LossesSignificant recurring operating and net losses depress returns on equity and shareholder value over time. Persistent unprofitability constrains reinvestment decisions, raises the probability of future capital raises, and increases sensitivity to execution or trial setbacks that could amplify dilution.
Small, Volatile Partner-derived Revenue BaseA modest research-fee revenue base that management expects to decline increases revenue volatility and makes near-term cash generation partner-dependent. Prioritizing internal programs reduces predictable partner fee inflows, heightening reliance on milestones and licensing outcomes to sustain long-term revenues.
AbCellera Biologics News
8QQ FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was €2.49 and its highest was €7.65 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is €1.43B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 8 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -€0.123 earnings per share for the quarter, beating the consensus estimate of -€0.15 by €0.027.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -€0.123 in its last earnings report, beating expectations of -€0.15. Following the earnings report the stock price went down -14.642%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in DE:8QQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.94 (76.62% Upside)
€8.94 (76.62% Upside)
Blogger Sentiment
Neutral
DE:8QQ Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $95.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
8QQ Company Deck
8QQ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive clinical and financial picture: compelling interim Phase I data for ABCL635 (favorable tolerability, strong PK/PD and sustained target engagement) with a clear near-term Phase II catalyst (Q3 2026), expanding pipeline progress, and a robust liquidity position (~$655M available including government funding). Headwinds include continued quarterly losses (~$43M), modest current revenue (~$8M) with expected declines in partner-derived research fees, a small potential tolerability signal at the highest dose (900 mg), blinded MAD data limiting full visibility, and remaining scientific/efficacy risk until Phase II readout. Overall, positives (clinical momentum, liquidity, and pipeline cadence) outweigh the negatives, but the company remains dependent on upcoming Phase II and other near-term milestones.View all DE:8QQ earnings summaries8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
8QQ Stock 12 Month Forecast
Average Price Target
€8.94
▲(76.62% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―